ChemoCentryx Trial of CCR2 Inhibitor for Pancreatic Cancer

21.04.2015 - ChemoCentryx, Inc, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, has begun enrolling patients with non-resectable...